Increased operational expenses and reduced cash reserves were cited. Roivant Sciences reports improved EPS for the second ...

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.26 per share a year ago. These ...

More recently, he has held consulting, advisory and investment partner roles with organisations including BIO, MIT, Roivant ...

Roivant Sciences Ltd (NASDAQ:ROIV) is set to release its Q2 2025 earnings on Nov 12, 2024. The consensus estimate for Q2 2025 ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...

Vivek Ramaswamy (American entrepreneur who founded Roivant Sciences) will also be very influential and will surely support ...

AB-101-001 is a Phase 1a/1b double-blind, randomized, placebo-controlled clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- ...

Strive Enterprises, a financial services company co-founded by former Republican presidential candidate Vivek Ramaswamy, has announced plans to move its headquarters to Dallas.

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

The U.S. is deploying a total of six nuclear equipped B-52s, an additional squadron of F-15E Strike Eagles, and more aerial ...

Strive Enterprises, co-founded by the former Republican presidential candidate, is also launching a wealth management ...

An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug ...